These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. Flynn PA; da Graca RL; Auld PA; Nesin M; Kleinman CS J Pediatr; 2005 Jul; 147(1):38-42. PubMed ID: 16027692 [TBL] [Abstract][Full Text] [Related]
11. Aminoterminal B-type natriuretic peptide (NT-proBNP) in the therapy of patent ductus arteriosus. Bagnoli F; Rossetti A; Casucci M; Mori A Minerva Pediatr; 2010 Jun; 62(3 Suppl 1):67-70. PubMed ID: 21089722 [TBL] [Abstract][Full Text] [Related]
13. Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates. Gokulakrishnan G; Kulkarni M; He S; Leeflang MM; Cabrera AG; Fernandes CJ; Pammi M Cochrane Database Syst Rev; 2022 Dec; 12(12):CD013129. PubMed ID: 36478359 [TBL] [Abstract][Full Text] [Related]
14. B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. Mine K; Ohashi A; Tsuji S; Nakashima J; Hirabayashi M; Kaneko K Acta Paediatr; 2013 Aug; 102(8):e347-52. PubMed ID: 23611593 [TBL] [Abstract][Full Text] [Related]
15. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. Sanjeev S; Pettersen M; Lua J; Thomas R; Shankaran S; L'Ecuyer T J Perinatol; 2005 Nov; 25(11):709-13. PubMed ID: 16222347 [TBL] [Abstract][Full Text] [Related]
16. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. El-Khuffash AF; Slevin M; McNamara PJ; Molloy EJ Arch Dis Child Fetal Neonatal Ed; 2011 Mar; 96(2):F133-7. PubMed ID: 21071684 [TBL] [Abstract][Full Text] [Related]
17. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Ramakrishnan S; Heung YM; Round J; Morris TP; Collinson P; Williams AF Acta Paediatr; 2009 Aug; 98(8):1254-9. PubMed ID: 19432837 [TBL] [Abstract][Full Text] [Related]
18. Serial N-terminal pro-brain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life. Letshwiti JB; Sirc J; O'Kelly R; Miletin J Eur J Pediatr; 2014 Nov; 173(11):1491-6. PubMed ID: 24898778 [TBL] [Abstract][Full Text] [Related]
19. [Value of amino-terminal pro-brain natriuretic peptide as a predictive marker of symptomatic patent ductus arteriosus in preterm infants]. Lu KS; Guo XL; Lv JF; Huang SL; Yang CH; Zou ZH; Chen ZJ; Lai CH; Yang BY Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1160-4. PubMed ID: 26575871 [TBL] [Abstract][Full Text] [Related]
20. Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. Weir FJ; Smith A; Littleton P; Carter N; Hamilton PA Acta Paediatr; 1992 Sep; 81(9):672-5. PubMed ID: 1421905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]